SecBot SecBot

CPRX

CATALYST PHARMACEUTICALS, INC.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001369568 Biotech & Drug Discovery
No price
Market cap
$3.9B
Mid cap
Median target
$31.50
range $31.50–32.00
Short interest
340.3K
≈0.3% of shares · −95.7%
Days to cover
1.0
at average volume
Insider net
$0
no open-market trades · since Jul 15
New fund stakes
0
Q3 2026 13F · 33 exits
Filing reports
16
analyzed by SecBot
SecBot read BEARISH 2 reports · 90 days
Balance 1 bearish · 0 bullish · 1 mixed oldest → newest, height = score
Avg score

Price

Daily candles with volume.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells since Jul 15. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBEARISH

    Q3 2026: 1 added (0 new), 33 trimmed or exited.

  • EstimatesRISING

    Current-quarter EPS estimate $0.675 → $0.736 over 90 days. 1 up, 0 down in 30 days.

  • Short sellersCOVERING

    Short interest −95.7% to 340.3K shares. 1.0 days to cover, ≈0.3% of shares.

Who's buying

13F· Q3 2026
0
new positions
33
exits

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action May 2026
Recent actions
DateFirmActionRating
May 28, 2026HC Wainwright & Co.
DOWNGRADE
DOWNGRADENeutral

Washington

Corporate Lobbying

10 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Insider ledger

Form 4
$0
open-market buys or sells · since Jul 15
DateInsiderTypeValue
Jul 15, 2026
DENKHAUS DONALD A
Director
Jul 15, 2026
TO ISSUER20,000 sh
Jul 15, 2026
DENKHAUS DONALD A
Director
Jul 15, 2026
TO ISSUER$15.7M
Jul 15, 2026
DENKHAUS DONALD A
Director
Jul 15, 2026
TO ISSUER33,500 sh
Jul 15, 2026
DENKHAUS DONALD A
Director
Jul 15, 2026
TO ISSUER15,000 sh
Jul 15, 2026
DENKHAUS DONALD A
Director
Jul 15, 2026
TO ISSUER23,248 sh
Jul 15, 2026
Tierney David S
Director
Jul 15, 2026
TO ISSUER33,500 sh
Jul 15, 2026
Tierney David S
Director
Jul 15, 2026
TO ISSUER18,115 sh
Jul 15, 2026
DENKHAUS DONALD A
Director
Jul 15, 2026
TO ISSUER30,000 sh

Earnings setup

Estimates
$0.74
EPS estimate, this quarter
+9%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q$0.74$0.74–$0.74+6.3%$154.6M
Current FY$3.17$3.17–$3.17+11.0%$636.2M
Next FY$3.18$2.58–$3.55+1.5%$717.9M
Next Q$0.82$0.82–$0.82+12.1%$162.1M

Short side

FINRA· Jul 15, 2026
340,264
shares short
-95.7%
vs prior settlement
1.0
days to cover
≈0.3%
of shares outstanding
Trading halts
Jul 14, 2026DeletionResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 4, 2026 SEC
Three institutional investors, Swedbank Ab, Principal Financial Group, and Dimensional Fund Advisors, completely…
INST-CLUSTER · Impact 4/10
Nov 3, 2026 Earnings calendar
CPRX Q3 2026 Earnings Scheduled · 2026-11-03
Sep 30, 2026 Inst.
Swedbank AB · EXIT
0 shares ($0.00)
Sep 30, 2026 Inst.
PRINCIPAL FINANCIAL GROUP INC · EXIT
0 shares ($0.00)
Aug 22, 2026 SEC
CPRX saw a mixed institutional cluster in Q2 2026: 23 buyers added $226.9M in new positions (led by JPMorgan, American…
INST-CLUSTER · Impact 5/10
Jul 24, 2026 SEC
Catalyst Pharmaceuticals filed a Form 15-12G to terminate its SEC registration under Section 12(g), effective July 24…
15-12G · Impact 9/10
Jul 15, 2026 Insider
DENKHAUS DONALD A disposed of 20,000 shares
Director
Jul 15, 2026 Insider
DENKHAUS DONALD A disposed of 498,773 shares
Director @ $31.50 ($15.7M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
3 drugs tracked · Drug pipeline →
Recent

SecBot reports

16 filings · 6 bullish · 5 bearish · 1 mixed · 4 neutral
All CPRX filing & press-release reports (16)